Prostate-Specific Membrane Antigen (PSMA)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (10 December 2022) | Viewed by 46162
Special Issue Editor
Interests: PSMA Imaging and Therapy; Circulating Tumor Cells (CTC); Prostate Cancer
Special Issue Information
Dear Colleagues,
This Special Issue is about Prostate-Specific Membrane Antigen (PSMA), which has been the subject of a huge number of studies during the last 25 years. PSMA is a transmembrane protein, highly expressed by prostate epithelial cells and strongly upregulated in prostate cancer. PSMA expression levels are directly correlated to androgen independence, metastasis, and prostate cancer progression.
PSMA targeted imaging and therapy have significantly changed the management of patients with prostate cancer: Prospective studies could show the superiority of PSMA PET compared to conventional imaging modalities for the staging of prostate cancer. Moreover, within the last decades, different radiolabeled ligands have been used for therapy in Phase I and II studies with extremely promising response rates in end stage prostate cancer patients. Lately, one of those ligands has been under evaluation in a Phase III trial (VISION).
This special issue will highlight the importance of the radio targeted diagnostic and therapy in prostate cancer using PSMA ligands.
Prof. Kambiz Rahbar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PSMA
- PET
- Radioligand therapy
- CRPC
- CTC